SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

• Published in: Frontiers in oncology Vol. 13; p. 1229655
• Main Authors: Hijano, Diego R., Ferrolino, Jose A., Swift, Elizabeth G., Michaels, Carolyn A., Max, Anita, Hayden, Randall T., Wolf, Joshua, Dallas, Ronald H., Greene, William L., Richardson, Julie L., Hakim, Hana, Morton, Ted H., Cross, Shane J.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 03.08.2023
• Subjects: cancer; coronavirus; hematopoietic cell transplant; immunocompromised; monoclonal antibodies; Oncology
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1229655

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.